The Pediatric Oncology Group (POG) member institutions' collaborative research efforts are providing important information concerning the biology and treatment of most types of pediatric leukemias and solid tumors. Multidisciplinary participation in the cooperative studies and in the administrative and scientific activities of the POG forms the foundation for the University of Mississippi Medical Center's (UMC) clinical and laboratory research programs in pediatric oncology. The UMC is the only center in Mississippi providing comprehensive cancer care for the children of the state. UMC's POG affiliate institution, the USAF Medical Center Keesler, makes available specialized pediatric oncology care for children of military personnel from Mississippi and surrounding states. During the next grant period, the UMC principal investigator (PI) will serve as the POG New Acute Lymphocytic Leukemia (ALL) Committee's associate chair and as the chair of the New ALL Reference Laboratory Directors' Committee. The UMC has served as the coordinating institution for each of the POG's sequential New ALL laboratory classification studies and will coordinate the POG 9400 ALinC 16 classification protocol during the next grant period. These classification studies are defining specific biologic subgroups of ALL and demonstrating prognostic and pharmacologic differences among the subgroups. Patients are routed through the classification study to specially designed treatment protocols for B-Precursor, T-ALL, and B-ALL, respectively. Other biologic characteristics, such as cytogenetic findings and DNA Index, are combined with the traditional age/WBC factors in determining risk group and treatment protocol for patients with B-Precursor ALL. The UMC study coordinator's office assimilates all POG reference laboratory and local institution classification data in time for its use in treatment assignment. The Keesler affiliate PI participates in the planning and coordination of the POG's SIMAL studies for patients with relapsed ALL.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA015989-23
Application #
2007182
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1979-01-01
Project End
2000-12-31
Budget Start
1997-01-01
Budget End
1997-12-31
Support Year
23
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Mississippi Medical Center
Department
Pediatrics
Type
Schools of Medicine
DUNS #
928824473
City
Jackson
State
MS
Country
United States
Zip Code
39216
Wacker, Pierre; Land, Vita J; Camitta, Bruce M et al. (2007) Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol 29:627-32
Whitehead, V M; Shuster, J J; Vuchich, M J et al. (2005) Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia 19:533-6
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Goorin, Allen M; Harris, Michael B; Bernstein, Mark et al. (2002) Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 20:426-33
Winter, S S; Sweatman, J; Shuster, J J et al. (2002) Bone marrow stroma-supported culture of T-lineage acute lymphoblastic leukemic cells predicts treatment outcome in children: a Pediatric Oncology Group study. Leukemia 16:1121-6
Mahoney Jr, D H; Cohen, M E; Friedman, H S et al. (2000) Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro Oncol 2:213-20
Pullen, J; Shuster, J J; Link, M et al. (1999) Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia 13:1696-707
Borowitz, M J; Rubnitz, J; Nash, M et al. (1998) Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study. Leukemia 12:1764-70
Camitta, B M; Pullen, J; Murphy, S (1997) Biology and treatment of acute lymphocytic leukemia in children. Semin Oncol 24:83-91
Martin, P L; Look, A T; Schnell, S et al. (1996) Comparison of fluorescence in situ hybridization, cytogenetic analysis, and DNA index analysis to detect chromosomes 4 and 10 aneuploidy in pediatric acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 18:113-21

Showing the most recent 10 out of 23 publications